Table 2.
Polygenic risk score (PRS) of ulcerative colitis (UC) as a predictor of all-grade and severe immune checkpoint inhibitor-mediated colitis (IMC) in the replication cohort (BioVU) and meta-analysis (GeRI and BioVU), using logistic regression model and stratified analysis assessing the association between PRSUC and all-grade/severe IMC by type of therapy
| IMCa | Replication cohort BioVU | Meta-analysis GeRI+ BioVU | ||||
|---|---|---|---|---|---|---|
| OR per SD | 95% CI | p | OR per SD | 95% CI | p | |
| All-grade | 1.29 | 0.98–1.69 | 0.07 | 1.35 | 1.12–1.64 | 2 x 10−3 |
| Severe | 1.39 | 1.02–1.90 | 0.04 | 1.49 | 1.18–1.88 | 9 x 10−4 |
| Stratified analysis by type of therapy: All-grade IMC | ||||||
| Therapyb | Replication cohort BioVU | Meta-analysis GeRI + BioVU | ||||
| Anti-PD1/Anti-PD-L1 monotherapy | 1.25 | 0.88–1.78 | 0.21 | 1.35 | 1.07–1.69 | 0.01 |
| Anti-PD1/Anti-PD-L1 + Anti-CTLA4 | 2.04 | 0.79–5.28 | 0.14 | 1.80 | 0.95-3.41 | 0.07 |
| Anti-CTLA4 monotherapy | 0.92 | 0.67–1.26 | 0.59 | - | - | - |
| Stratified analysis by type of therapy: Severe IMC | ||||||
| Therapyb | Replication cohort BioVU | Meta-analysis GeRI + BioVU | ||||
| Anti-PD1/Anti-PD-L1 monotherapy | 1.47 | 0.96–2.25 | 0.08 | 1.48 | 1.10–1.98 | 9 x 10−3 |
| Anti-PD1/Anti-PD-L1 + Anti-CTLA4 | 1.89 | 0.74–4.86 | 0.19 | 2.20 | 1.07–4.53 | 0.03 |
| Anti-CTLA4 monotherapy | 1.00 | 0.71–1.40 | 0.99 | - | - | - |
All p-values are two-sided.
Statistically significant results are highlighted in bold.
IMC immune checkpoint inhibitor-mediated colitis, OR odds ratio, SD standard deviation, CI confidence interval.
aModels are adjusted for age at diagnosis, sex, type of therapy, and 5 principal components.
bModels are adjusted for age at diagnosis, sex, and 5 principal components.